查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲细胞化验分析市场：分析与预测（2023-2032）
市场调查报告书
商品编码
1410671

欧洲细胞化验分析市场：分析与预测（2023-2032）

Europe Cell-Based Assay Market: Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 75 Pages | 商品交期: 1-5个工作天内

价格

欧洲细胞化验分析市场规模预计将从 2023 年的 51.7 亿美元增至 2032 年的 111.2 亿美元，在 2023-2032 年预测期内复合年增长率为 8.88%。

在製药业的药物研发努力以及这些检测相对于传统方法的独特优势的推动下，细胞化验分析市场正在快速成长。模仿人类生理学、早期预测药物疗效和毒性以及个体化医疗保健的能力正在推动需求。慢性病的增加和政府的支持措施进一步放大了这一趋势，市场有望大幅扩张。

主要市场统计数据
预测期 2023-2032
2023年评估价值 51.7亿美元
2032年预测 112亿美元
复合年增长率 8.88%

由于多种因素的综合作用，欧洲细胞化验分析市场正在经历快速成长。製药和生物技术领域的快速成长，重点是高效的药物研发和个人化医疗，正在推动对这些强大工具的需求。细胞化验分析提供了一种比传统动物模型更贴近人类且更具成本效益的替代方案，可快速筛检候选药物并更深入地了解作用机制。对学术研究的投资增加以及政府促进生命科学创新的努力进一步支持了这一转变。然而，高昂的设备成本和严格的法律规范挑战需要策略合作伙伴关係和技术进步，才能充分发挥这个快速发展的市场的潜力。

该报告考察了欧洲细胞化验分析市场，并提供了市场概述、按国家和公司分類的趋势以及进入市场的公司概况。

目录

执行摘要

第一章 定义

第二章 研究范围

第三章调查方法

第四章市场概况

  • 市场介绍
    • 细胞化验分析类型
  • 工业细胞化验分析的现况与未来状况
  • 细胞化验分析市场的新兴技术与应用
  • 当前市场规模和成长潜力，十亿美元，2022-2032
  • COVID-19 对细胞化验分析市场的影响
    • 对细胞化验分析公司的影响

第五章业界考察

  • 概述
  • 欧洲法律要求和框架

第六章市场动态

  • 概述
  • 影响分析
    • 市场驱动因素
    • 市场抑制因素
    • 市场机会

第七章竞争形势

  • 竞争形势概览
    • 主要进展
    • 产品发布和扩展活动
    • 併购活动
    • 协同效应
    • 许可证和合约活动
  • 市场占有率分析（2022）
  • 成长份额分析（2021-2022）
    • 成长份额分析（按公司）

第8章 欧洲

  • 概述
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他地区

第九章 公司简介

Product Code: BHL1787SS

“The Europe Cell-Based Assay Market Expected to Reach $11.12 Billion by 2032.”

Introduction to Europe Cell-Based Assay Market

The Europe cell-based assay market is expected to reach $11.12 billion by 2032 from $5.17 billion in 2023, at a CAGR of 8.88% during the forecast period 2023-2032. The Cell-Based Assay Market is surging, driven by the pharmaceutical industry's escalating drug discovery efforts and the inherent advantages of these assays over traditional methods. Their ability to mimic human physiology, predict drug efficacy and toxicity early, and personalize medicine fuels demand. This trend is further amplified by rising chronic disease prevalence and supportive government initiatives, fostering a market poised for significant expansion.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$5.17 Billion
2032 Forecast$11.12 Billion
CAGR8.88%

Market Introduction

The European cell-based assay market is experiencing a surge, fueled by a confluence of factors. The burgeoning pharmaceutical and biotechnology sectors, with their focus on efficient drug discovery and personalized medicine, are driving demand for these powerful tools. Cell-based assays offer a more human-relevant and cost-effective alternative to traditional animal models, allowing for rapid screening of drug candidates and a deeper understanding of their mechanisms of action. This shift is further bolstered by rising investments in academic research and government initiatives promoting life sciences innovation. However, challenges such as high instrumentation costs and stringent regulatory frameworks necessitate strategic partnerships and technological advancements to unlock the full potential of this rapidly evolving market.

Market Segmentation:

Segmentation 1: by Country

  • U.K.
  • France
  • Italy
  • Germany
  • Spain
  • Rest-of-Europe

Segmentation 2: by Company

  • Merck KGaA
  • Lonza Group AG

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.

Competitive Strategy: Key players in the Europe cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

  • 1.1. Inclusion and Exclusion Criteria

2. Research Scope

  • 2.1. Key Questions Answered in the Report:

3. Research Methodology

  • 3.1. Cell-Based Assay Market: Research Methodology
  • 3.2. Primary Data Sources
  • 3.3. Secondary Data Sources
  • 3.4. Market Estimation Model
  • 3.5. Criteria for Company Profiling

4. Markets Overview

  • 4.1. Market Introduction
    • 4.1.1. Types of Cell-Based Assays
  • 4.2. Current and Future State of Cell-Based Assays in Industries
  • 4.3. Emerging Technologies and Applications in the Cell-Based Assay Market
  • 4.4. Current Market Size and Growth Potential, $Billion, 2022-2032
  • 4.5. COVID-19 Impact on Cell-Based Assay Market
    • 4.5.1. Impact on Cell-Based Assay Companies

5. Industry Insights

  • 5.1. Overview
  • 5.2. Legal Requirements and Frameworks in Europe

6. Market Dynamics

  • 6.1. Overview
  • 6.2. Impact Analysis
    • 6.2.1. Market Drivers
      • 6.2.1.1. Increase in Demand for Cell-Based Assay in Drug Discovery and Development
      • 6.2.1.2. Rise in Life Sciences Research Investments
      • 6.2.1.3. Technological Advancements
    • 6.2.2. Market Restraints
      • 6.2.2.1. High Cost
      • 6.2.2.2. Lack of Standardization
    • 6.2.3. Market Opportunities
      • 6.2.3.1. Increased Focus on Regenerative Medicine
      • 6.2.3.2. Emergence of Novel Gene Editing Technologies

7. Competitive Landscape

  • 7.1. Competitive Landscape Overview
    • 7.1.1. Key Developments
    • 7.1.2. Product Launch and Expansion Activities
    • 7.1.3. Merger and Acquisition Activities
    • 7.1.4. Synergistic Activities
    • 7.1.5. License and Agreement Activities
  • 7.2. Market Share Analysis (2022)
  • 7.3. Growth-Share Analysis (2021-2022)
    • 7.3.1. Growth-Share Analysis (by Company)

8. Europe

  • 8.1. Overview
  • 8.2. Europe
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Rest-of-Europe

9. Company Profiles

  • 9.1. Overview
    • 9.1.1. Merck KGaA
      • 9.1.1.1. Company Overview
      • 9.1.1.2. Role of Merck KGaA in the Cell-Based Assay Market
      • 9.1.1.3. Major Product: Key Specifications
      • 9.1.1.4. Key Competitors
      • 9.1.1.5. Analyst Perspective
    • 9.1.2. Lonza Group AG
      • 9.1.2.1. Company Overview
      • 9.1.2.2. Role of Lonza Group AG in the Cell-Based Assay Market
      • 9.1.2.3. Major Product: Key Specifications
      • 9.1.2.4. Key Competitors
      • 9.1.2.5. Analyst Perspective

List of Tables

  • Table 1: Current and Future State of Cell-Based Assay in Industries
  • Table 2: Utilizing the Potential of Cell-Based Assays: Novel Instruments and Methodologies in 2020-2021

List of Figures

  • Figure 1: Impact Analysis of Drivers, Challenges, and Opportunities on the Cell-Based Assay Market
  • Figure 2: Cell-Based Assay Market (by Region), 2022
  • Figure 3: Cell-based Assay Market Methodology
  • Figure 4: Primary Research Methodology
  • Figure 5: Top-Down Approach (Segment-Wise Analysis)
  • Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 7: Cellular Processes Utilized to Investigate the Impacts in Cell-Based Assays
  • Figure 8: Emerging Technologies in the Cell-Based Assay Market
  • Figure 9: Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 10: Impact of COVID-19 on Cell-Based Assay Companies
  • Figure 11: Cell-Based Assay Market - Market Dynamics
  • Figure 12: Total U.S. Life Sciences Venture Capital Funding, $Billion, 2016-2021
  • Figure 13: Uses of Cell-based Assays in Regenerative Medicine
  • Figure 14: Share of Key Developments and Strategies, January 2020 to March 2023
  • Figure 15: Share of Product Launch and Expansion Activities (by Company), January 2020 to March 2023
  • Figure 16: Share of Merger and Acquisition Activities (by Company), January 2020 to March 2023
  • Figure 17: Share of Synergistic Activities (by Company), January 2020 to March 2023
  • Figure 18: Market Share Analysis for Cell-Based Assay Market, 2022
  • Figure 19: Growth-Share Analysis for Cell-Based Assay Market (by Company), 2021-2022
  • Figure 20: Cell-Based Assay Market Snapshot (by Region)
  • Figure 21: Cell-Based Assay Market (by Region), $Billion, 2022-2032
  • Figure 22: Europe Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 23: Europe: Market Dynamics
  • Figure 24: Europe Cell-Based Assay Market (by Country), $Billion, 2022-2032
  • Figure 25: Germany Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 26: U.K. Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 27: France Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 28: Italy Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 29: Spain Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 30: Rest-of-Europe Cell-Based Assay Market, $Billion, 2022-2032
  • Figure 31: Total Number of Companies Profiled
  • Figure 32: Merck KGaA: Product Portfolio
  • Figure 33: Lonza Group AG: Product Portfolio